Q2 expectations and ‘22-’24 estimate changes We forecast Q2 sales and adj. EBITDA of EUR 3.01m and EUR 0.90m, respectively, corresponding to organic sales growth of 33% y-o-y, and an adj. EBITDA margin of 30%. Following a change of analyst, we make some adjustments to our estimates. Our ‘22-‘24 top-line estimates are up by 1%, and the mix between the revenue streams is modified slightly. In addition, we make some opex adjustments, resulting in the ‘22e-‘23e adj. EBIT being raised by 4-10%.
New fair value range of SEK 36-62 per share Following the recent moves in our peer group, we lower our fair value range accordingly to SEK 36-62 per share from SEK 39-68. In addition, we note that the share is trading at 6.1x-5.0x EV/sales for ’22e-23e on our estimates, which is a tad above the digital health SaaS peer Carasent, a company with slightly lower expected ’21-‘23 growth and ‘23e EBITDA margin, acc ... Läs mer på ABG Sundal Collier
